Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tcr2 Therapeutics Inc (TCRR)

Tcr2 Therapeutics Inc (TCRR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,108
  • Shares Outstanding, K 39,262
  • Annual Sales, $ 0 K
  • Annual Income, $ -151,820 K
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.57
Trade TCRR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.20
  • Most Recent Earnings $-1.03 on 05/11/23
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.81
  • Number of Estimates 3
  • High Estimate -0.65
  • Low Estimate -0.92
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +1.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4800 unch
on 05/31/23
2.0400 -27.45%
on 05/08/23
-0.2850 (-16.15%)
since 04/28/23
3-Month
1.1521 +28.46%
on 03/03/23
2.0400 -27.45%
on 05/08/23
+0.2300 (+18.40%)
since 02/28/23
52-Week
0.8210 +80.27%
on 12/23/22
3.8800 -61.86%
on 08/15/22
-0.8200 (-35.65%)
since 05/27/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FOCS : 52.99 (-0.02%)
ROCC : 37.47 (-1.96%)
TCRR : 1.4800 (-5.73%)
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to...

TCRR : 1.4800 (-5.73%)
ADAP : 1.5800 (unch)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ROCC : 37.47 (-1.96%)
KBAL : 12.30 (-0.89%)
ADAP : 1.5800 (unch)
TCRR : 1.4800 (-5.73%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RADI : 15.00 (+0.20%)
ADAP : 1.5800 (unch)
TCRR : 1.4800 (-5.73%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ROCC : 37.47 (-1.96%)
RADI : 15.00 (+0.20%)
ADAP : 1.5800 (unch)
TCRR : 1.4800 (-5.73%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DSEY : 8.39 (unch)
ADAP : 1.5800 (unch)
TCRR : 1.4800 (-5.73%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

JNCE : 1.8800 (-2.59%)
ADAP : 1.5800 (unch)
TCRR : 1.4800 (-5.73%)
Moore Kuehn Encourages KBAL, DSEY, RADI, and TCRR Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

KBAL : 12.30 (-0.89%)
DSEY : 8.39 (unch)
RADI : 15.00 (+0.20%)
TCRR : 1.4800 (-5.73%)
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to...

TCRR : 1.4800 (-5.73%)
ADAP : 1.5800 (unch)
INVESTIGATION ALERT: Halper Sadeh LLC Investigates RADI, ADAP, TCRR, ROCC

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RADI : 15.00 (+0.20%)
ADAP : 1.5800 (unch)
TCRR : 1.4800 (-5.73%)
ROCC : 37.47 (-1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.7300
2nd Resistance Point 1.6800
1st Resistance Point 1.5800
Last Price 1.4800
1st Support Level 1.4300
2nd Support Level 1.3800
3rd Support Level 1.2800

See More

52-Week High 3.8800
Fibonacci 61.8% 2.7115
Fibonacci 50% 2.3505
Fibonacci 38.2% 1.9895
Last Price 1.4800
52-Week Low 0.8210

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar